Patents by Inventor Muralidhar Bondlela
Muralidhar Bondlela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160002142Abstract: The invention provides novel phenylglyoxylic acid derivatives, which may be useful as intermediates for preparing stereoisomerically enriched drug compounds. The invention also provides methods of making phenylglyoxylic acid derivatives, and uses of phenylglyoxylic acid derivatives.Type: ApplicationFiled: September 15, 2015Publication date: January 7, 2016Inventors: Dharma Rao Polisetti, Santhosh Kalpathy, Muralidhar Bondlela, Robert Carl Andrews, Thomas Scott Yokum, Eugene Campian, Rajashaker Kache
-
Patent number: 9175003Abstract: The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.Type: GrantFiled: January 23, 2015Date of Patent: November 3, 2015Assignee: vTv Therapeutics LLCInventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Santhosh Kalpathy, Stephen Thomas Davis, Thomas Scott Yokum
-
Patent number: 9162963Abstract: The invention provides novel phenylglyoxylic acid derivatives, which may be useful as intermediates for preparing stereoisomerically enriched drug compounds. The invention also provides methods of making phenylglyoxylic acid derivatives, and uses of phenylglyoxylic acid derivatives.Type: GrantFiled: July 3, 2013Date of Patent: October 20, 2015Assignee: vTv Therapeutics LLCInventors: Dharma Rao Polisetti, Kalpathy Santhosh, Muralidhar Bondlela, Robert Carl Andrews, Thomas Scott Yokum, Eugene Campian, Rajashaker Kache
-
Patent number: 9045461Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: March 26, 2014Date of Patent: June 2, 2015Assignee: TransTech Pharma, LLCInventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
-
Publication number: 20150148539Abstract: The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.Type: ApplicationFiled: January 23, 2015Publication date: May 28, 2015Inventors: Adnan M.M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, JR., Jennifer L.R. Freeman, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Santhosh Kalpathy, Stephen Thomas Davis, Thomas Scott Yokum
-
Patent number: 8987295Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.Type: GrantFiled: December 6, 2012Date of Patent: March 24, 2015Assignee: TransTech Pharma, LLCInventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
-
Publication number: 20140206660Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: TransTech Pharma, LLCInventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
-
Patent number: 8741900Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: February 21, 2013Date of Patent: June 3, 2014Assignee: TransTech Pharma, LLCInventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari, Rongyuan Xie
-
Publication number: 20130296599Abstract: The invention provides novel phenylglyoxylic acid derivatives, which may be useful as intermediates for preparing stereoisomerically enriched drug compounds. The invention also provides methods of making phenylglyoxylic acid derivatives, and uses of phenylglyoxylic acid derivatives.Type: ApplicationFiled: July 3, 2013Publication date: November 7, 2013Inventors: Dharma Rao Polisetti, Kalpathy Santhosh, Muralidhar Bondlela, Robert Carl Andrews, Thomas Scott Yokum, Eugene Campian, Rajashaker Kache
-
Patent number: 8431575Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: GrantFiled: February 15, 2011Date of Patent: April 30, 2013Assignee: TransTech Pharma, Inc.Inventors: Devi R Gohimukkula, David Robert Jones, Ghassan Qabaja, Jeff J Zhu, Jeremy T Cooper, William K Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Suparna Gupta, Anitha Hari, Raju B Gowda, Robert C Andrews
-
Patent number: 8383644Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.Type: GrantFiled: June 29, 2010Date of Patent: February 26, 2013Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James Quada, Jennifer L. R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
-
Publication number: 20110230458Abstract: The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.Type: ApplicationFiled: February 15, 2011Publication date: September 22, 2011Applicant: TransTech Pharma, Inc.Inventors: Devi R. Gohimukkula, David Jones, Ghassan Qabaja, Jeff J. Zhu, Jeremy T. Cooper, William K. Banner, Kurt Sundermann, Muralidhar Bondlela, Mohan Rao, Pingzhen Wang, Raju B. Gowda, Robert C. Andrews, Suparna Gupta, Anitha Hari
-
Publication number: 20110160198Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.Type: ApplicationFiled: June 29, 2010Publication date: June 30, 2011Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Adnan M.M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James Quada, Jennifer L.R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
-
Publication number: 20100036150Abstract: The invention relates to compounds, compositions, methods of using and processes for producing optically active ?-hydroxy derivatives using a combination of a chemical and biochemical methods. The process comprises reacting an ester compound with a racemic compound in the presence of an enzyme to obtain compounds (compositions and methods). The compounds produced may be useful for starting materials for physiologically active materials, functional materials and the like.Type: ApplicationFiled: October 24, 2007Publication date: February 11, 2010Inventors: Dharma Rao Polisetti, Daniel P. Christen, Mustafa Guzel, Thomas Scott Yokum, Muralidhar Bondlela
-
Publication number: 20090247536Abstract: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.Type: ApplicationFiled: June 12, 2009Publication date: October 1, 2009Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Mohan Rao, Muralidhar Bondlela, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Suvi Simila, Tan Ren
-
Patent number: 7582673Abstract: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.Type: GrantFiled: October 20, 2005Date of Patent: September 1, 2009Assignee: High Point Pharmaceuticals, LLCInventors: Adnan M. M. Mjalli, Bapu Gaddam, Mohan Rao, Muralidhar Bondlela, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Suvi Simila, Tan Ren
-
Patent number: 7501538Abstract: This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and/or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.Type: GrantFiled: August 6, 2004Date of Patent: March 10, 2009Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Guoxiang Huang, Murty N. Arimilli, Thomas Scott Yokum, Jeff Jiqun Zhu, Muralidhar Bondlela
-
Patent number: 7459472Abstract: This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. Compounds of Formula (I) may be useful for treating viral infections including orthopox viruses, either alone or in combination with other therapeutic agents.Type: GrantFiled: August 6, 2004Date of Patent: December 2, 2008Assignee: TransTech Pharma, Inc.Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Murty N. Arimilli, Mohan Rao, Mustafa Guzel, Muralidhar Bondlela, Xiao-Chuan Guo, Guoxiang Huang
-
Publication number: 20060106089Abstract: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.Type: ApplicationFiled: October 20, 2005Publication date: May 18, 2006Inventors: Adnan Mjalli, Bapu Gaddam, Mohan Rao, Muralidhar Bondlela, Ramesh Gopalaswamy, Robert Andrews, Stephen Davis, Suvi Simila, Tan Ren
-
Publication number: 20050059713Abstract: This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. Compounds of Formula (I) may be useful for treating viral infections including orthopox viruses, either alone or in combination with other therapeutic agents.Type: ApplicationFiled: August 6, 2004Publication date: March 17, 2005Inventors: Adnan Mjalli, Robert Andrews, Murty Arimilli, Mohan Rao, Mustafa Guzel, Muralidhar Bondlela, Xiao-Chuan Guo, Guoxiang Huang